Hoechst 33342 alters luciferase gene expression in transfected BC3H-1 myocytes

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 9, 2003, Pages 1124-1132

  Zhang, Xinbo ^b   Kiechle, Frederick L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HOE 33342; LUCIFERASE;

ANIMAL CELL; APOPTOSIS; CELL DEATH; CELL MEMBRANE PERMEABILITY; COMPLEX FORMATION; CONFERENCE PAPER; DNA PROTEIN COMPLEX; DRUG EFFECT; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; IONIZING RADIATION; MUSCLE CELL; NONHUMAN; PROMOTER REGION; RECEPTOR AFFINITY;

ANIMALS; BENZIMIDAZOLES; BINDING SITES; BISBENZIMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUORESCENT DYES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LUCIFERASES; MYOCYTES, SMOOTH MUSCLE; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TATA BOX; TATA-BOX BINDING PROTEIN; TIME FACTORS; TRANSCRIPTION FACTORS, TFII; TUMOR CELLS, CULTURED;

EID: 0041333798     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Chen AY, Yu C, Gatto B, Liu LF. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci U S A. 1993;90:8131-8135.
2. Reddy BS, Sondhi SM, Lawn JW. Synthetic DNA minor groove-binding drugs. Pharmacol Ther. 1999;84:1-111.
3. Pjura PE, Grzeskowiak K, Dickerson RE. Binding of Hoechst 33258 to the minor groove of B-DNA. J Mol Biol. 1987;197:257-271.
4. Chiu L, Cherwinski H, Ransom J, Dunne JF. Flow cytometric ratio analysis of the Hoechst 33342 emission spectrum: multiparametric characterization of apoptotic lymphocytes. J Immunol Methods. 1996;189:157-171.
5. Kurose I, Higuchi H, Yonei Y, et al. Rat Kupffer cell-derived nitric oxide suppresses proliferation and induces apoptosis of syngeneic hepatoma cells. Gastroenterology. 1996;111:1058-1070.
6. Smith PJ, Lacy M, Debenham PG, Watson JV. A mammalian cell mutant with enhanced capacity to dissociate a bis-benzimidazole dye-DNA complex. Carcinogenesis. 1988;9:485-490.
7. Lopukhov LV, Ponomareva AA, Yagodina LO. Amyloglucosidase suppresses interference by glycogen in quantification of DNA using Hoechst 33258 dye. Biotechniques. 2002;32:1250-1256.
8. Bester MJ, Potgieter HC, Vermaak WJH. Cholate and pH reduce interference by sodium dodecyl sulfate in the determination of DNA with Hoechst. Anal Biochem. 1994;223:299-305.
9. 6G] AATTCGCG) complexed with Hoechst 33258 and Hoechst 33342. EMBO J. 1992;11:225-232.
10. 4) DNA sequences. Biochim Biophys Acta. 2002;1576:136-142.
11. Elstein KH, Zucker RM. Comparison of cellular and nuclear flow cytometric techniques for discriminating apoptotic subpopulations. Exp Cell Res. 1994;211:322-331.
12. Filatov MV, Varfolomeeva EY. Active dissociation of Hoechst 33342 from DNA in living mammalian cells. Mutat Res. 1995;327:209-215.
13. Kiechle FL, Zhang X. Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta. 2002;326:27-45.
14. Durand RE, Olive PL. Cytotoxicity, mutagenicity and DNA damage by Hoechst 33342. J Histochem Cytochem. 1982;30:111-116.
15. Lyubimova NV, Coultas PG, Yuen K, Martin RF. In vivo radioprotection of mouse brain endothelial cells by Hoechst 33342. Br J Radiol. 2001;74:77-82.
16. Zhang X, Kiechle FL. Hoechst 33342-induced apoptosis in BC3H-1 myocytes. Ann Clin Lab Sci. 1997;27:260-275.
17. Zhang X, Kiechle FL. Hoechst 33342 induces apoptosis in hepatoma cells and inhibits topoisomerase I in vivo. J Clin Ligand Assay. 1998;21:62-67.
18. Kiechle FL, Zhang X. Hoechst 33342 induces apoptosis inhibits topoisomerase I, and alters TATA box binding protein/DNA complexes in HT-144 melanoma cells. Arab J Lab Med. 1999;25:151-161.
19. Zhang X, Chen J, Davis B, Kiechle FL. Hoechst 33342 induces apoptosis in HL-60 cells and inhibits topoisomerase I in vivo. Arch Pathol Lab Med. 1999;123:921-927.
20. Zhang X, Kiechle FL. Mechanism of Hoechst 33342-induced apoptosis in BC3H-1 myocytes. Ann Clin Lab Sci. 1998;28:104-114.
21. Zhang X, Kiechle FL. Hoechst 33342 induces apoptosis and alters TATA box binding protein/DNA complexes in nuclei from BC3H-1 myocytes. Biochem Biophys Res Commun. 1998;248:18-21.
22. Kiechle FL, Zhang X. Hoechst 33342 induces apoptosis and alters TATA box binding protein/DNA complexes in nuclei from HL-60 cells. J Clin Ligand Assay. 1998;21:413-417.
23. Jerome KR, Chen Z. Apoptosis in HL-60 cells and topoisomerase I in vivo [letter]. Arch Pathol Lab Med. 2000;124:802-803.
24. Chen JC, Zhang X, Singleton T, Kiechle FL. Hoechst 33342 depolarizes the transmembrane potential in myelogenous leukemic cells [abstract]. Cytometry. 2001;46:314.
25. Kiechle FL, Borvkovych V, Zhang X, Malinski T. Nitric oxide release during Hoechst 33342-induced apoptosis [abstract]. FASEB J. 2000;14:A398.
26. Zhang X, Kiechle FL. Disruption of replication protein A/single-stranded DNA complexes during apoptosis in HL-60 cells. Biochem Biophys Res Commun. 2001;287:865-869.
27. Zhang X, Kiechle FL. Hoechst 33342-induced apoptosis is associated with intracellular accumulation of E2F-1 protein in BC3H-1 myocytes and HL-60 cells. Arch Pathol Lab Med. 2001;125:99-104.
28. Zhang X, Kiechle FL. Hoechst 33342-induced apoptosis is associated with decreased immunoreactive topoisomerase I and topoisomerase I-DNA complex formation. Ann Clin Lab Sci. 2001;31:187-198.
29. Calabrese EJ. Apoptosis: biphasic dose responses. Crit Rev Toxicol. 2001;31:607-613.
30. Waring MJ. DNA modification and cancer. Annu Rev Biochem. 1981;50:159-192.
31. Chiang SY, Welch J, Rauscher F III, Beerman TA. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry. 1994;33:7033-7040.
32. White RJ. Basal transcription by RNA polymerase II. In: Gene Transcription. Mechanisms and Control. Oxford, England: Blackwell Science; 2001:50-71.
33. Zhang X, Kiechle FL. Electrophoretic mobility shift assay: a useful technique for detecting DNA-binding proteins. In: Molecular Diagnostics and Immunopathology Check Sample. Vol 5. No. MDI 01-2. Chicago, Ill: American Society of Clinical Pathologists; 2001:15-31.
34. Ofenstein JP, Dandurand DM, Kiechle FL. Assessment of mitochondrial function in cells grown in tissue culture. Ann Clin Lab Sci. 1992;22:406-413.
35. Jensen J, Serup P, Karlsen C, Nielsen TF, Madsen OD. mRNA profiling of rat islet tumors reveals nkx 6.1 asa beta-cell-specific homeodomain transcription factor. J Biol Chem. 1996;31:18749-18758.
36. Hardenbol P, Van Dyke MW. In vitro inhibition of c-myc transcription by mithramycin. Biochem Biophys Res Commun. 1992;185:553-558.
37. Osborne SA, Tonissen KF. pRL-TK induction can cause misinterpretation of gene promoter activity. Biotechniques. 2002;33:1240-1242.
38. Ofenstein JP, Kiechle FL, Dandurand DM, Belknap WM, Moore KH, Holmes RD. Lactate oxidation for the detection of mitochondrial dysfunction in human skin fibroblasts. Anal Biochem. 1993;210:332-336.
39. Kiechle FL, Zhang X. The postgenomic era. Implications for the clinical laboratory. Arch Pathol Lab Med. 2002;126:255-262.
40. Beerman TA, McHugh MM, Sigmund R, Lown JW, Rao KE, Bathini Y. Effects of analogs of the DNA minor groove binder Hoechst 33258 on topoisomerase II and I mediated activities. Biochim Biophys Acta. 1992;1131:53-61.
41. Werstuck G, Green MR. Controlling gene expression in living cells through small molecule-RNA interactions. Science. 1998;282:296-298.
42. Berry MD, Boulton AA. Glyceraldehyde-3-phosphate dehydrogenase and apoptosis. J Neurosci Res. 2000;60:150-154.
43. Smith PJ, Bell SM, Dee A, Sykes H. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons. Carcinogenesis. 1990;11:659-665.
44. Chiang SY, Azizkhan JC, Beerman TA. A comparison of DNA-binding drugs as inhibitors of E2F1-and Sp1-DNA complexes and associated gene expression. Biochemistry. 1998;37:3109-3115.
45. Rosfjord E, Lamb K, Rizzino A. Cryptic promoter activity within the backbone of a plasmid commonly used to prepare promoter/reporter gene constructs. In Vitro Cell Dev Biol Anim. 1994;30A:477-481.
46. Thirunavukkarasu K, Miles RR, Halladay DL, Onyia JE. Cryptic enhancer elements in luciferase reporter vectors respond to the osteoblast-specific transcription factor Osf2/Cbfa. Biotechniques. 2000;28:506-510.
47. Hong SJ, Chae H, Kim K-S. Promoterless luciferase reporter gene is transactivated by basic helix-loop-helix transcription factors. Biotechniques. 2002;33:1236-1240.
48. Dombroski AJ, Walter WA, Record MT Jr, Siegele DA, Gross CA. Polypeptides containing highly conserved regions of transcription initiation factor sigma 70 exhibit specificity of binding to promoter DNA. Cell. 1992;70:501-512.
49. Dombroski AJ, Walter WA, Gross CA. Amino-terminal amino acids modulate sigma-factor DNA-binding activity. Genes Dev. 1993;7:2446-2455.
50. Tan S, Garrett KP, Conaway RC, Conaway JW. Cryptic DNA-binding domain in the C terminus of RNA polymerase II general transcription factor RAP30. Proc Natl Acad Sci U S A. 1994;91:9808-9812.
51. Huet J, Conesa C, Carles C, Sentenac A. A cryptic DNA binding domain at the COOH terminus of TFIIIB70 affects formation, stability, and function of preinitiation complexes. J Biol Chem. 1997;272:18341-18349.
52. Han B, Zhang JT. Regulation of gene expression by internal ribosome entry sites or cryptic promoters: the eIF4G story. Mol Cell Biol. 2002;22:7372-7384.